Frontlight ResearchEarly access
CompletedNo phase
Role of ARMA in Selective Subset of Refractory GERD Patients.
Key facts
- Who runs it
- Asian Institute of Gastroenterology, India
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 50 people enrolled
- Started
- 30 Mar 2023
- Ended
- 30 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ARMA
- UGI Endoscopy
- Record updated
- 4 April 2025
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Normal Upper Gastrointestinal endoscopy And
- 24 hour pH Impedance: AET < 6%, More than 80 refluxes
- Patients who are willing to give consent for the procedure
Who cannot take part
- Previous esophageal or gastric surgery
- Large Hiatal hernia >3cm
- Lower esophageal sphincter (LES) pressure >15 mm Hg
- Paraesophageal hernia
- GE flap valve grade IV (Hill's classification)
- Barretts esophagus
- Esophageal dysmotility
- ASA physical status >II
- Pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To study the role of a novel endoscopic treatment technique (ARMA) in GERD patients who doesn't respond to PPI therapy (Proton Pump Inhibitor).
The 2 groups in the trial
- ARMA GroupExisting treatment, for comparison
All patients in this group will undergo Anti-reflux mucosal ablation using upper gastrointestinal endoscopy. The stomach will be insufflated with CO2 to visualize the cardia in retroflex view.
Treatment: ARMA
- Sham GroupSham treatment, for comparison
UGI Endoscopy will be performed under Propofol based sedation with scope kept inside for at least 5 minutes.
Treatment: UGI Endoscopy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Role of ARMA in Selective Subset of Refractory GERD Patients- A Randomized Sham Control Trial.
- Record updated
- 4 April 2025